Evaluating the efficacy, safety, tolerability of use and treatment adherence in two different dosing schedules, pre-costagionale and costagionale, of a sublingual allergoid (Lais Parietaria)administered to patients suffered from oculorhinitis with or without bronchial asthma by Parietaria. Randomized double-blind, multicenter, parallel group, placebo-controlled. - ParLais/09

开始日期2009-10-26

申办/合作机构

Lofarma SpA

100 项与 Parietaria pollen allergy immunotherapy(Lofarma SpA) 相关的临床结果

登录后查看更多信息

100 项与 Parietaria pollen allergy immunotherapy(Lofarma SpA) 相关的转化医学

登录后查看更多信息

100 项与 Parietaria pollen allergy immunotherapy(Lofarma SpA) 相关的专利（医药）

登录后查看更多信息

项与 Parietaria pollen allergy immunotherapy(Lofarma SpA) 相关的文献（医药）

2020-01-01·Respiratory Medicine3区 · 医学

Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study

3区 · 医学

Article

作者: Marcello Albanesi ; Valentina Laudadio ; Filomena Loconte ; Maria Filomena Caiaffa ; Silvana Strada ; Eustachio Nettis ; Elisabetta Damiani ; Elisabetta Di Leo ; Anita Lotti ; Roberto Loiodice ; Enza Mastromarco ; Saverio Nenna ; Maria Pietrafesa ; Giuseppe Bariletto ; Massimo Bilancia ; Annamaria Carbonara ; Danilo Di Bona ; Luigi Macchia ; Lucia Masciopinto ; Stefania Magistà ; Andrea Nico ; Anna Simona Rucco ; Georgios Kourtis ; Antonella Lovecchio ; Vito Cataldo ; Irene Fiorino

BACKGROUNDSafety and treatment compliance are still considered important shortcomings of subcutaneous immunotherapy (SCIT).OBJECTIVETo assess the rate of side effects (SE) to SCIT and treatment compliance at a hospital medically supervised facility.METHODSA retrospective review of patients with allergic rhino-conjunctivitis (ARC) with or without asthma, who received SCIT to mites and pollens from 1988 to 2018, was performed. The information was collected from patient's allergen immunotherapy forms that had been prospectically filled in by expert physicians.RESULTSTwo thousand two hundred patients (50.2% males; mean age 29.4 ± 11.7 years) received 3037 SCIT courses. A total of 91,187 injections were given, with a mean SCIT duration of 2.5 ± 1.9 years. Nine hundred fifty-seven patients (43.5%) were compliant as they completed the minimally required treatment duration of 3 years. A total of 1087 SE (1.2% of all injections; 76.8% local reactions) were reported in 513 patients (23.3%). There were 42 anaphylactic reactions (in 29 patients) during the study period; two of these were severe. Adrenalin was administered only once. No anaphylactic shock was reported. Only 39 patients (1.8%) discontinued SCIT because of SE, the majority of whom (24; 61.5%) because of systemic reactions (urticaria, asthma, anaphylaxis). Parietaria vaccines were the most frequently associated to SE. Female gender, number of vaccines administered (2 vaccine vs. 1 vaccine) and year of SCIT inception (1996-2018 vs. 1988-1995) were independently associated to SE.CONCLUSIONSCIT, although not absolutely free of risk, is safe and well tolerated. There is still room for improvement of treatment compliance.

2018-07-01·International Immunopharmacology2区 · 医学

Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis

2区 · 医学

Article

作者: Cibella, Fabio ; Caruso, Massimo ; Polosa, Riccardo ; Tringali, Giovanni ; Campagna, Davide ; Emma, Rosalia ; Amaradio, Maria Domenica

Prevalence of allergic diseases is increasing worldwide. Allergen-specific immunotherapy (ASIT) is potentially the only curative treatment for allergy, but there is a lack of reliable methods to monitor the immune responses to ASIT and to predict clinical efficacy. Recently, the definition of allergen sensitivity threshold (CD-Sens) by Basophil Activation Tests has been suggested as potential method in this context. The aim of this study was to compare trends of CD-Sens, measured by the markers CD63 and CD203c, and clinical symptoms in subjects with allergic rhinitis receiving Sublingual Immunotherapy (SLIT). 26 rhinitis patients allergic to Parietaria were selected and matched into two groups; a SLIT treated group (SG) and a reference group (RG) treated by traditional anti-allergic medications. Visual Analogue Scale (VAS) score for the four cardinal symptoms of rhinitis and peripheral blood was collected before the first dose of SLIT (T₀) and after 12 months (T₁₂) to define the severity of the symptoms and the sensitivity of basophils to Parietaria. The comparison between T0 and T12 in SG patients showed a significant decrease of symptom severity (VAS score) and an increased tolerability of basophils to Parietaria (CD-Sens) both by CD63 and CD203c. But, only CD203c seems to be correlated with the clinical symptoms. These data corroborate the hypothesis that SLIT could change the immunological course of allergic sensitization already in the first year, and that an immunological parameter as CD-Sens measured by CD63 and CD203c expression on stimulated basophils could be useful to monitor the changes in the immune system.

2014-05-01·European annals of allergy and clinical immunology

Adverse reaction to sublingual Parietaria vaccine following an ultra-rush induction.

Article

作者: Ciccarelli, A ; Calabrò, C ; Scala, G

In the treatment of respiratory allergies Sublingual Immunotherapy (SLIT) represents a valid alternative to Subcutaneous Immunotherapy (SCIT) for its better safety profile. We describe a case of acute severe asthma following the first maintenance dose of SLIT in a boy allergic to Parietaria pollen. At the initiation of therapy, the patient was in healthy condition and his asthma appeared to be under control. An ultra-rush induction had given no reaction. Despite the good safety profile of SLIT, clinicians should be aware of the risk of adverse effects when prescribing SLIT for respiratory allergies.

100 项与 Parietaria pollen allergy immunotherapy(Lofarma SpA) 相关的药物交易

登录后查看更多信息